Resverlogix Corp.

Publications

Publications, Abstracts & Posters

The 13th International Conference on Alzheimer's & Parkinson's Diseases 2017: Apabetalone, a BET Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia that Contribute to Neurodegenerative Disease. Authors: Ewelina Kulikowski, Dean Gilham, Laura Tsujikawa, Sylwia Wasiak, Christopher Halliday, Rowan Lind, Cyrus Calosing, Brooke Rakai, Jan O. Johansson, Michael Sweeney, Ravi Jahagirdar and Norman C.W. Wong.

AD/PD 2017 Poster Link

ACC 2017: Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) In Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway. Authors: Ewelina Kulikowski, Cyrus Calosing, Laura Tsujikawa, Sylwia Wasiak, Dean Gilham, Christopher Halliday, Michael Sweeney, Jan Johansson, and Norman Wong.

ACC 2017 Poster Link

ASN 2016: Apabetalone Reduces Levels of Key Markers Involved in Vascular Calcification. Authors: Ewelina Kulikowski, Dean Gilham, Laura Tsujikawa, Sylwia Wasiak, Kamyar Kalantar-Zadeh, Christopher Halliday, Jan Johansson, Michael Sweeney, and Norman Wong.

ASN 2016 Poster Link

AHA 2016: Apabetalone (RVX-208) Reduces Expression of Acute Phase Response Markers in Vitro and in Patients with Cardiovascular Disease. Authors: Ewelina Kulikowski, Sylwia Wasiak, Dean Gilham, Cyrus Calosing, Laura Tsujikawa, Christopher Halliday, Michael Sweeney, Jan Johansson, and Norman C. W. Wong

AHA 2016 Poster Link

ESC Congress - August 28, 2016: Modulation of the complement cascade in cardiovascular disease patients by a bromodomain and extraterminal (BET) protein inhibitor

ESC Poster Link

AHA 2015: RVX-208 a Selective Bromodomain and Extra-Terminal BET Protein Inhibitor Acts on Several Pathways to Benefit Cardiovascular Risks. Authors: Ewelina Kulikowski, Sylwia Wasiak, Dean Gilham, Christopher Halliday, Kenneth Lebioda, Michael Sweeney, Jan Johansson, Norman Wong.

Link: http://circ.ahajournals.org/content/132/Suppl_3/A17127.abstract?sid=985beb63-a69e-4477-aaa1-25123ff48862 (abstract 17127)

ASN 2015: Alkaline Phosphatase Lowering by Selective BET Inhibition, a Novel Mechanism for MACE Reduction in High Risk CVD, Diabetes and CKD Patients; a Post-hoc Analysis of Phase 2b Studies with RVX-208. Authors: Kamyar Kalantar-Zadeh, Jan Johansson, Michael Sweeney, Ken Lebioda, Ewelina Kulikowski,  Christopher Halliday, Norman Wong.

Link: https://www.asn-online.org/abstracts/ (abstract TH-PO609)

RVX-208, Apabetalone, a First-in-Class Epigenetic BET Inhibitor, on ALP and eGFR in Subjects with CVD and CKD; a Post-hoc Analysis of ASSERT, SUSTAIN and ASSURE Clinical Trials. Authors: Kamyar Kalantar-Zadeh, Jan Johansson, Michael Sweeney, Ken Lebioda, Ewelina Kulikowski, Christopher Halliday, Norman Wong.

Link: https://www.asn-online.org/abstracts/ (abstract TH-PO666)

ACCRVX-208 the first selective bromodomain extra-terminal protein inhibitor being developed for patients with high residual risks of cardiovascular disease. Authors: Norman CW Wong; Jan Johansson; Kenneth Lebioda; Christopher Halliday; Ewelina Kulikowski. Link: http://content.onlinejacc.org/article.aspx?articleid=2197900

ATVBEffects of RVX-208 a Selective Bromodomain Extra-Terminal Protein Inhibitor Beyond Raising ApoA-I/HDL. Authors: Ewelina Kulikowski, Sylwia Wasiak, Sarah Attwell, Christopher Halliday, Dean Gilham, Laura Tsujikawa, Ravi Jahagirdar, Kenneth Lebioda, Jan Johansson, Mike Sweeney. Link: http://atvb.ahajournals.org/content/35/Suppl_1/A338.abstract?sid=a20e22bc-a1e3-4f49-88b1-c2d77f6a3afc

EASRVX-208 a selective bromodomain Extra-Terminal protein inhibitor reduces MACE in patients with high residual risks of cardiovascular disease, a post-hoc analysis. Authors: N.C.W. Wong, J.O. Johansson, K. Lebioda, C. Halliday, E. Kulikowski. Link: http://www.atherosclerosis-journal.com/article/S0021-9150(15)00263-4/abstract

ADAEffects of the ApoA-I Inducer RVX-208 on Glucose Metabolism in Individuals with Prediabetes. Authors: Andrew L. Siebel, Melissa F. Formosa, Alaina K. Natoli, Medini Reddy-Luthmoodoo, Andrew L. Carey, Gerrit Van Hall, Jim D. Otvos, Kerry-Anne Rye, Jan Johansson, Allan Gordon, Norman Wong, Philip Barter, Stephen J. Duffy, Bronwyn A. Kingwell. Link: http://www.abstractsonline.com/pp8/#!/3699/presentation/10373

EASDRVX-208 acts via an epigenetic mechanism to lower Major Adverse Cardiovascular Events (MACE) in patients with atherosclerosis and especially in those with diabetes mellitus. Authors: N.C.W. Wong, E. Kulikowski, L. Tsujikawa, D. Gilham, S. Wasiak, C. Halliday, K. Lebioda, J.O. Johansson, M. Sweeney. Link: http://www.easdvirtualmeeting.org/resources/rvx-208-acts-via-an-epigenetic-mechanism-to-lower-major-adverse-cardiovascular-events-mace-in-patients-with-atherosclerosis-and-especially-in-those-with-diabetes-mellitus--2

ISARVX-208 a selective bromodomain extra-terminal protein inhibitor Reduces MACE in Patients with high Residual Risks of Cardiovascular Disease. Authors: N.C.W. Wong, J.O. Johansson, K. Lebioda, E. Kulikowski, C. Halliday. Link: http://www.eventure-online.com/eventure/public/publicAbstractView.form?id=256145&congressId=8753

ESCEffects of RVX-208 on major adverse cardiac events (MACE), apolipoprotein A-I and High Density Lipoproteins; A post-hoc analysis from the pooled SUSTAIN and ASSURE clinical trials. Authors: J.A.N.O. Johansson, A.F. Gordon, C. Halliday, N.C. Wong. Link: http://spo.escardio.org/abstract-book/presentation.aspx?id=127290